Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Novatti Group announces IBM World Wire network foundation member (ASX:NOV)

Highlights Novatti joins IBM World Wire network as a foundation member IBM World Wire network built on blockchain technology for faster, cheaper and real time global payments. IB...read more

Novatti Group announces $2 million Capital Raising (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company) is pleased to announced it has received commitments via a placement to professional and sophisticated investors to raise approximately $2 million (...read more

Novatti Group announces SendFX selects Novatti as its key supplier of technology (ASX:NOV)

11 March 2019 SendFX Remittance and Cross-border payments network - strategic investment & supply agreement Highlights SendFX remittance and cross-border payments network selects N...read more

Novatti Announces Wechat Pay Extends Chinapayments.com (ASX:NOV)

Highlights Wechat Pay now available on Chinapayments.com for the payment of Australian bills Chinapayments.com sets a processing record of $696k in February Novatti Group Limited (ASX:NOV) ...read more

Noxopharm to Expedite Veyonda Clinical Program (ASX:NOX)

Internal strategic review triggered by growing confidence in Veyonda becoming a major new anti-cancer drug and the need to confirm commercial and clinical strategies Confirmed aim to develop Veyo...read more

Noxopharm Announces Combination of Veyonda plus Radiotherapy Delivers Clinical Benefits (ASX:NOX)

- Interim (12-week) DARRT-1 readout - Combination Veyonda + low-dose radiotherapy well tolerated - PSA, pain and tumour responses at higher doses - 24-week readout to indicate longevity of re...read more

Noxopharm, December 2018 Quarterly Report Appendix 4C (ASX:NOX)

Veyonda clinical program continuing on plan Imminent release of interim DARRT-1 clinical data DARRT program to be expanded and expedited based on early data LuPIN-1 data to be released mi...read more

Noxopharm Announces Principal Investigator Discusses LuPIN-1 Study (ASX:NOX)

Lu-PIN-1 Study two-thirds enrolled Study testing ability of Veyonda to boost effect of Novartis experimental drug Noxopharm to initiate LuPIN-2 study. SYDNEY, January 14, 2019: Noxopharm (...read more

Noxopharm Announces DARRT-1 Study to Advance on Basis of Positive Clinical Data (ASX:NOX)

Trial to enrol final 12 patients at 1200mg dose Based on positive safety and clinical response data Next scheduled review late-January 2019 SYDNEY, December 11, 2018: Noxopharm (ASX:NOX) a...read more

Noxopharm Announces Positive Data from CEP-1 Study of Veyonda (ASX:NOX)

Final CEP-1 data confirm tolerability of Veyonda alone and in combination with carboplatin Halt in progression of cancer growth in 50% of patients Study provides proof-of-concept for well-tol...read more

Noxopharm, 2018 Annual General Meeting Presentation (ASX:NOX)

Noxopharm at-a-glance Australian biotechnology company. Offices Sydney, New York, Hong Kong Playing to our strength.... isoflavonoid drug platform Aiming to bring Veyonda® to market as...read more

Noxopharm to Present Clinical Data at COSA 2018 Annual Meeting (ASX:NOX)

Clinical Oncology Society of Australia Provides updates on CEP-1 and DARRT-1 clinical studies Confirms tolerability of Veyonda Evidence of durable halt of tumour progression in both studi...read more

Noxopharm Releases Latest Corporate Presentation November 2018 (ASX:NOX)

Investment Highlights Leader in the development of isoflavonoid-based therapeutics, an emerging field of drug development - Novel family of G-protein inhibitors blocking key signaling pathways ...read more

Noxopharm Releases September Quarter 2018 Appendix 4C (ASX:NOX)

Sydney, 26 October 2018: Noxopharm (ASX:NOX) today releases its Appendix 4C for the quarter ended 30 September 2018, as well as providing guidance on the next 12-18 months. This report is presented...read more

Noxopharm Announces Key Executive Appointment (ASX:NOX)

Chief Medical Officer appointed Early clinical trial data leads to expanded clinical trial program Company prepares for pre-commercial phase Sydney, 22 October 2018: Noxopharm (ASX:NOX) is...read more

Viewing: 1 - 15 of 200 Previous | Next